Turning the Tide
on Zytiga®-Resistant Metastatic
Castration-Resistant Prostate Cancer (mCRPC)
Adding Onvansertib to Daily Zytiga is Increasing the Duration of Response to Treatment and Progression-Free Survival
New Therapeutic Options are Needed to Overcome Resistance to SOC Androgen Receptor Signaling Inhibitors (ARSi)
Resistance develops to treatment with standard of care ARSi’s within 9-15 months.
ARSi’s offer a median overall survival (mOS) benefit of only ~4 months.
No effective treatment options are available for the up to 40% of mCRPC patients with an AR-V7 mutation.
Limited options for patients once resistant to abiraterone
New treatment options are needed to extend the duration of response to ARSi’s and increase overall survival.
Why onvansertib is a promising option for
mCPRC: Overcoming resistance to Zytiga
Onvansertib in combination with Zytiga (abiraterone) demonstrates synergy in
mCRPC and significantly increases the arrest of tumor cell division.
Treatment Response and Duration
26% (5/19) DCR at 12 weeks in patients with at least 1 AR alteration
associated with abiraterone resistance
Our Clinical Programs
KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Leveraging the synergy of onvansertib to increase duration and response of overall survival.
Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.